Goldman Sachs Group Inc Fulcrum Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 586,351 shares of FULC stock, worth $5.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

586,351

Previous 1,143,536 48.72%

Holding current value

$5.08 Million

Previous $7.87 Million 35.02%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$6.34 - $8.84 $3.53 Million - $4.93 Million	-557,185 Reduced 48.72%	586,351 $5.11 Million
Q2 2025 Aug 14, 2025	BUY	$2.51 - $7.38 $1.86 Million - $5.47 Million	740,936 Added 184.04%	1,143,536 $7.87 Million
Q1 2025 May 09, 2025	SELL	$2.88 - $5.08 $402,215 - $709,462	-139,658 Reduced 25.75%	402,600 $1.16 Million
Q4 2024 Feb 11, 2025	SELL	$2.97 - $4.84 $1.15 Million - $1.87 Million	-385,703 Reduced 41.56%	542,258 $2.55 Million
Q3 2024 Nov 14, 2024	BUY	$3.18 - $9.74 $1.17 Million - $3.58 Million	367,469 Added 65.56%	927,961 $3.31 Million

Q2 2024 Aug 13, 2024	SELL	$5.98 - $9.31 $1.49 Million - $2.33 Million	-249,778 Reduced 30.83%	560,492 $3.48 Million
Q1 2024 May 15, 2024	SELL	$6.7 - $12.0 $410,261 - $734,796	-61,233 Reduced 7.03%	810,270 $7.65 Million
Q4 2023 Feb 13, 2024	BUY	$3.18 - $6.86 $1.95 Million - $4.2 Million	612,276 Added 236.19%	871,503 $5.88 Million
Q3 2023 May 14, 2024	SELL	$3.25 - $6.08 $1.99 Million - $3.72 Million	-612,276 Reduced 70.26%	259,227 $1.15 Million
Q3 2023 Nov 14, 2023	SELL	$3.25 - $6.08 $417,641 - $781,310	-128,505 Reduced 33.14%	259,227 $1.15 Million
Q2 2023 May 14, 2024	BUY	$2.26 - $3.8 $203,221 - $341,699	89,921 Added 30.19%	387,732 $1.28 Million
Q2 2023 Aug 14, 2023	BUY	$2.26 - $3.8 $203,221 - $341,699	89,921 Added 30.19%	387,732 $1.28 Million
Q1 2023 May 14, 2024	SELL	$2.83 - $13.99 $49,856 - $246,461	-17,617 Reduced 5.59%	297,811 $848,000
Q1 2023 May 11, 2023	SELL	$2.83 - $13.99 $49,856 - $246,461	-17,617 Reduced 5.59%	297,811 $848,000
Q4 2022 May 14, 2024	SELL	$5.01 - $8.35 $146,803 - $244,671	-29,302 Reduced 8.5%	315,428 $2.3 Million
Q4 2022 Feb 13, 2023	SELL	$5.01 - $8.35 $146,803 - $244,671	-29,302 Reduced 8.5%	315,428 $2.3 Million
Q3 2022 May 14, 2024	BUY	$4.92 - $9.1 $297,291 - $549,867	60,425 Added 21.25%	344,730 $2.79 Million
Q3 2022 Nov 10, 2022	BUY	$4.92 - $9.1 $297,291 - $549,867	60,425 Added 21.25%	344,730 $0
Q2 2022 May 14, 2024	SELL	$4.2 - $24.0 $2.47 Million - $14.1 Million	-587,198 Reduced 67.38%	284,305 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$4.2 - $24.0 $195,984 - $1.12 Million	46,663 Added 19.64%	284,305 $1.39 Million
Q1 2022 May 16, 2022	BUY	$9.96 - $23.65 $1.52 Million - $3.61 Million	152,759 Added 179.96%	237,642 $5.62 Million
Q4 2021 Feb 14, 2022	BUY	$14.0 - $28.44 $313,334 - $636,515	22,381 Added 35.81%	84,883 $1.5 Million
Q3 2021 Nov 10, 2021	BUY	$7.28 - $30.97 $455,014 - $1.94 Million	62,502 New	62,502 $1.76 Million

Others Institutions Holding FULC

# of Institutions

133

Shares Held

55.4M

Call Options Held

176K

Put Options Held

13.5K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $451M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Fulcrum Therapeutics, Inc. Transaction History